Core Viewpoint - Yiming Anke-B (01541.HK) has successfully completed a placement agreement, raising approximately HKD 345.1 million for various research and operational purposes [1] Group 1: Placement Details - The placement involved the successful allocation of 24.2 million shares at a price of HKD 14.50 per share, representing about 5.94% of the company's issued share capital prior to the placement [1] - The shares allocated account for approximately 6.11% of the total issued H-shares before the placement and about 5.61% and 5.76% of the issued share capital and H-shares, respectively, after the placement [1] Group 2: Use of Proceeds - Approximately 40% of the net proceeds will be allocated to fund the research and development of IMM2510 and IMM27M for the treatment of solid tumors [1] - About 20% will be used for the development of IMM01 (Tideglusib) [1] - Approximately 10% will be directed towards the research of IMM0306 [1] - The remaining 30% will be utilized to supplement the company's working capital and for general corporate purposes [1]

Group 1 - Company Innovent Biologics (1541.HK) announced a placement of 24.2 million new H-shares, representing approximately 5.61% of the enlarged share capital, to raise HKD 351 million (USD 45 million) at a price of HKD 14.5 per share, which is a discount of about 12.97% from the previous closing price of HKD 16.66 [3] - The estimated net proceeds of approximately HKD 345 million will be used to fund the research and development of IMM2510 and IMM27M for the treatment of solid tumors, as well as for the development of IMM01 (Tislelizumab) and IMM0306, and to supplement working capital and general corporate purposes [3] - The company has submitted an application to the National Medical Products Administration for a Phase III clinical trial of IMM2510 for the treatment of immune-resistant non-small cell lung cancer (NSCLC) [3] Group 2 - The company's stock opened lower on Thursday, trading at HKD 14.46 at noon, down 13.21%. However, the stock has increased by 180% year-to-date [3]

Core Viewpoint - The company plans to issue a total of 24.2 million new H-shares at a price of HKD 14.50 per share, representing a discount of approximately 12.97% from the closing price of HKD 16.66 on October 8, 2025 [1] Fundraising Details - The total estimated gross proceeds from the placement are approximately HKD 350.9 million, with net proceeds estimated at around HKD 345 million [1] - The net proceeds will be allocated as follows: - Approximately 40% for funding the research and development of IMM2510 and IMM27M for the treatment of solid tumors - Approximately 20% for funding the research and development of IMM01 (Tideglusib) - Approximately 10% for funding the research and development of IMM0306 - Approximately 30% for supplementing the company's working capital and general corporate purposes [1]

Core Viewpoint - The company plans to issue a total of 24.2 million new H-shares at a price of HKD 14.50 per share, representing a discount of approximately 12.97% from the closing price of HKD 16.66 on October 8, 2025 [1] Fundraising Details - The total estimated gross proceeds from the placement are approximately HKD 350.9 million, with net proceeds estimated at around HKD 345 million [1] - The net proceeds will be allocated as follows: - Approximately 40% for funding the research and development of IMM2510 and IMM27M for the treatment of solid tumors - Approximately 20% for funding the research and development of IMM01 (Tideglusib) - Approximately 10% for funding the research and development of IMM0306 - Approximately 30% for supplementing the company's working capital and general corporate purposes [1]

Core Viewpoint - The company, 宜明昂科-B (01541.HK), has announced a placement agreement with Credit Suisse to issue 24.2 million new H-shares at a price of HKD 14.50 per share, representing a discount of approximately 12.97% from the last closing price of HKD 16.66 [1] Group 1: Placement Details - The placement will involve the issuance of 24.2 million new H-shares, which accounts for about 5.94% of the company's total issued share capital and approximately 6.11% of the total issued H-shares as of the announcement date [1] - The estimated total gross proceeds from the placement are approximately HKD 350.9 million, with net proceeds expected to be around HKD 345.1 million [1] Group 2: Use of Proceeds - Approximately 40% of the net proceeds will be allocated to fund the research and development of IMM2510 and IMM27M for the treatment of solid tumors [1] - About 20% of the net proceeds will be used to fund the research and development of IMM01 (Tideglusib) [1] - Approximately 10% will be allocated for the research and development of IMM0306, while around 30% will be used to supplement the company's working capital and for general corporate purposes [1]

Core Viewpoint - The company, 宜明昂科-B (01541), has seen a significant stock price increase following the announcement of its clinical trial applications for IMM2510, a treatment for immune-resistant non-small cell lung cancer (NSCLC) [1] Group 1: Clinical Trial Developments - The company has submitted an application to the National Medical Products Administration for a Phase III clinical trial of IMM2510 for treating immune-resistant NSCLC [1] - Two additional Phase III registration clinical trials for different types of lung cancer have also been submitted recently [1] Group 2: Clinical Trial Results - Data from a Phase I study presented at the 2025 World Lung Cancer Conference showed that among 17 evaluable patients with advanced squamous NSCLC who had previously received immunotherapy, the objective response rate was 35.3% and the disease control rate was 76.5% [1] - The median duration of response was reported at 7.59 months, while the median progression-free survival was 9.4 months [1] Group 3: Future Plans - Based on the promising results, the company plans to further validate the efficacy and safety of IMM2510 through the upcoming Phase III clinical trials, aiming to provide more effective treatment options for lung cancer patients [1]

Core Viewpoint - The stock of Iminco-B (01541) has increased by over 9%, currently trading at 15.77 HKD, following the submission of a Phase III clinical trial application for IMM2510 to treat immune-resistant non-small cell lung cancer (NSCLC) [1] Company Developments - Iminco has submitted an application to the National Medical Products Administration for a Phase III clinical trial of IMM2510 aimed at treating immune-resistant NSCLC [1] - The company has also submitted two additional Phase III registration clinical trials for different types of lung cancer [1] Clinical Trial Results - Recent Phase I study data presented at the 2025 World Lung Cancer Conference showed that among 17 evaluable patients with advanced squamous NSCLC who had previously received immunotherapy, the objective response rate and disease control rate for IMM2510 were 35.3% and 76.5%, respectively [1] - The median duration of response was reported at 7.59 months, while the median progression-free survival was 9.4 months [1] - Based on these results, the company plans to further validate the efficacy and safety of IMM2510 through Phase III clinical trials, aiming to provide more effective treatment options for lung cancer patients [1]

Core Viewpoint - The stock of Yiming Oncology-B (01541) has increased by over 6%, currently trading at 15.15 HKD with a transaction volume of 45.67 million HKD, following the announcement of new clinical trial applications for its drug IMM2510 [1] Group 1: Clinical Developments - Yiming Oncology has submitted an application to the National Medical Products Administration for a Phase III clinical trial of IMM2510, aimed at treating immune therapy-resistant non-small cell lung cancer (NSCLC) [1] - The company has also recently submitted two additional Phase III registration clinical trials for different types of lung cancer [1] Group 2: Research and Development Pipeline - According to a recent report from Guoyuan International, the company's research pipeline is continuously expanding, enhancing its risk resistance capabilities [1] - The clinical efficacy data for the CD47CD20 dual antibody (IMM0306) is reported to be excellent, with potential to become a significant drug in the autoimmune field [1] - Yiming Oncology is recognized as a global innovator in CD47 fusion proteins, with a rich pipeline and broad application prospects in oncology and autoimmune diseases [1]

Core Viewpoint - Yiming Oncology-B (01541) saw a stock increase of over 7%, currently trading at 14.4 HKD with a transaction volume of 29.21 million HKD, following the announcement of clinical trial applications for its drug IMM2510 aimed at treating immune therapy-resistant non-small cell lung cancer (NSCLC) [1] Group 1: Clinical Trial Developments - The company has submitted an application to the National Medical Products Administration for a Phase III clinical trial of IMM2510 for treating immune therapy-resistant NSCLC [1] - Additionally, two Phase III registration clinical trials for different types of lung cancer have been submitted recently [1] Group 2: Research Data - Recent Phase I study data presented at the 2025 World Lung Cancer Conference showed that among 17 evaluable patients with advanced squamous NSCLC who had previously received immune therapy, IMM2510 achieved an objective response rate (ORR) of 35.3% and a disease control rate (DCR) of 76.5% (13/17) [1] - The median duration of response (DoR) was reported as 7.59 months (95% CI: 4.07 - NA), and the median progression-free survival (PFS) was 9.4 months (95% CI: 1.87 - NA) [1]

Core Viewpoint - The company has submitted an application for a Phase III clinical trial of IMM2510 for the treatment of immune therapy-resistant non-small cell lung cancer (NSCLC) to the National Medical Products Administration of China [1] Group 1: Clinical Trial Developments - The company has recently submitted two Phase III registration clinical trials for different types of lung cancer [1] - The I phase study data presented at the 2025 World Lung Cancer Conference showed an objective response rate (ORR) of 35.3% and a disease control rate (DCR) of 76.5% among 17 evaluable patients with advanced squamous NSCLC who had previously received immune therapy [1] - The median duration of response (DoR) was reported as 7.59 months, and the median progression-free survival (PFS) was 9.4 months [1] Group 2: Future Plans - Based on the promising results from the I phase study, the company plans to further validate the efficacy and safety of IMM2510 through the Phase III clinical trials [1] - The aim is to provide more effective treatment options for lung cancer patients [1]